Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents.

NCT01770379 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

242

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

BIOLOGICAL: Secukinumab (AIN457)
BIOLOGICAL: Placebo

Sponsor

Novartis Pharmaceuticals